The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led ...

Breaking news and analysis from time.com. Politics, world news, photos, video, tech reviews, health, science, and ...

Cancer cells often survive treatment by fixing the DNA damage that therapy is meant to cause. Researchers found that UNI418 ...

Among patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations, nearly half (48.8%) did not receive a PARP inhibitor, despite recent FDA approvals and recent trials ...

PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers. Niraparib approved for all-comers whose ...

Poly (ADP-ribose) polymerase (PARP) inhibitors are effective in cells with homologous recombination (HR) deficiency, including BRCA1/2 mutation. However, PARP inhibitors remain a therapeutic challenge ...

In patients with advanced epithelial ovarian cancer, first-line maintenance therapy with PARP inhibitors was associated with a progression-free survival benefit compared with standard chemotherapy ...

SAN DIEGO -- Saruparib, an investigational selective PARP1 inhibitor, showed promising activity in patients with certain homologous recombination repair (HRR)-deficient breast cancers, while limiting ...

What if a new combination of cancer drugs could sound an alarm, alerting the body's immune system to invoke a targeted ...

Breast cancer (BC) is among the primary causes of cancer-related mortality among women worldwide. A 2025 analysis, utilizing global data from the year of 2022, confirms that BC remains the leading ...

ovarian cancer new treatments ...